Innovative solutions
    for more effective diagnostics




Client Care





Last news

Projet scientifique RADAR

Le projet RADAR (COOTECH) à pour objectif de développer de nouveaux tests d’identification de résistances aux antibiotiques.

Ce projet réalisé par Coris BioConcept en partenariat avec la société Synabs passe par la création de réactifs nécessaires au développement de nouveaux tests ainsi qu’à l’amélioration de tests existants afin d’étendre leur champ d’utilisation et permettra à Coris BioConcept d’étendre la gamme R.E.S.I.S.T. dédiée à ces identifications.

Cette gamme de tests d’identification de résistances aux antibiotiques permettra aux laboratoires de diagnostic d’améliorer leurs réponses aux besoins des cliniciens pour mieux prendre en charge la prévention des infections et une utilisation raisonnée des antibiotiques.

Ce projet d’un budget de 1,66 millions d’euros est financé à hauteur de 570.600 euros par les sociétés partenaires et bénéficie de 1,09 millions d’euros de subsides publics (40% FEDER, 60% Région Wallonne).


Le Fonds européen de développement régional et la Wallonie
investissent dans votre avenir.

OXA-23 K-SeT: the new solution to detect OXA-23 carbapenemase


The global spread of carbapenem-resistant Acinetobacter spp., and particularly A. baumanii, in healthcare settings causes a major threat to patient survival. Worldwide, drug-resistant Acinetobacter spp. are responsible for serious nosocomial outbreaks, mostly in intensive care units. Even though different resistance mechanisms have been described, production of Amber Class D oxacillinases OXA-23-like hydrolysis enzymes is the most frequent acquired mechanism.

Fast and accurate detection of OXA-23-producing strains remains challenging at the laboratory level. Specific identification of oxacillinase-expressing Acinetobacter requires genotypic molecular assays that remain expensive and not commercially available. Immunochromatography lateral flow tests are however cost-effective and convenient to detect drug hydrolyzing enzymes.

Today, a large panel of lateral flow tests to detect carbapenemase-expressing Enterobacteriacea, named “RESIST”, is commercialized by the Belgian company Coris BioConcept. In order to fulfill the unmet need for fast and reliable detection of drug-resistant Acinetobacter, Coris BioConcept developed a new lateral flow assay, “OXA-23 K-SeT”, for the specific identification of OXA-23-mediated carbapenem-resistant in Acinetobacter spp. from a single colony.

With results available in less than 15 minutes, this easy-to-use and instrument-free rapid test represents the first phenotypic, specific and non-molecular confirmatory assay for OXA-23 detection. It will expand the RESIST range of products already adopted nowadays by routine and reference laboratories worldwide, offering an additional tool to ensure the successful treatment of patients and prevent the spread of carbapenemase-producing bacteria in healthcare settings.


OXA-23 K-SeT

TRAPIST, a new diagnostic system


Coris BioConcept has always been committed to developing new technologies and products so its customers can perform more rapidly and accurately the detection and identification of infectious agents.

For more than 6 years, Coris has set up throughout two european projects a new R&D diagnostic platform called TRAPIST : The Rapid Advanced PCR & Immunoassay SysTem.

TRAPIST V6 is a fully automated instrument that performs multiplex diagnostic testings.
It is intended to be used in clinical laboratories for fast and easy multiplex diagnostics with disposable microfluidic chips.
Results are available within an hour. The platform enables a wide range of molecular assays as well as immunoassays.

 Img_Blog_Trapist_Machine_cercle          Img_Blog_Trapist_Puce_cercle

Coris BioConcept’s lab-on-a-chip is a disposable device that combines multiplex PCR amplification and detection by hybridization on a membrane in a microfluidic environment.
Used in conjunction with the Trapist V6 automated system, the disposable microfluidic chip supports all the steps of a rapid, specific and sensitive multiplex diagnostic from a single DNA sample preparation.
DNA sample and reagents are introduced into the chip by a simple and convenient procedure before being automatically processed by the Trapist V6 system.
The entire chip is airtight, preventing carry-over contamination with amplified DNA.

Want to discover how it works ?

Contact us for more information

Coris BioConcept at MEDICA Trade Fair 2015



Medica Trade Fair 2015

As every year Coris BioConcept will be exhibiting at MEDICA Trade Fair 2015 in Düsseldorf (Germany) from 16 to 19 November.

MEDICA is the world‘s largest medical marketplace annually organized in Europe. Attending MEDICA Trade Fair means having new opportunities to meet experts from the diagnostic field and to start new professional partnerships.

You will have the opportunity to discover our totally new product caller TRAPIST which is a new diagnostic platform that combines microfluidic and multiplex technologies.

Meet Coris BioConcept

Coris BioConcept is a middle-sized company (SME) specialized in developing, manufacturing and marketing rapid diagnostic tests (see our products).

For more than 15 years we provide rapid diagnostic products with high quality, easy to use and accessible everywhere to everybody. Our vision is to be innovative and global market leader in in vitro diagnostic in a sustainable economy that respects the environment and the person!

So, we gladly invite you to meet us at our booth 1F38 from November 16 to 19 !

Coris BioConcept Booth

Dr Thierry LECLIPTEUX (CEO & CSO) or Dr Christel BOUDRY (Product specialist & Business developer) will be pleased to meet you there.


Please do not hesitate to Contact us for any other information.

Best regards,

Coris BioConcept Team

Chips4Life Final Workshop

The final workshop of the EC-funded FP7 project Chips4Life will take place from 9am-6pm on the 29th of June 2015 at the CHU de Liège, Belgium.


Chips4Life aimed to develop a multiplex diagnostic test that will help clinicians to rapidly establish the agents responsible for a respiratory pathology in patients.

Don’t hesitate to participate and register now for this Chips4Life worship !


You can contact us for more details, or directly download the workshop’s programme.

Carbapenemase-Producing Enterobacteriaceae (CPE)

Coris BioConcept
 has always been committed to developing new technologies and products so its customers can perform more rapidly and accurately the detection and identification of infectious agents.

To face the growing problem of antibiotic-resistant bacteria, we have developed a new family of tests under the brand name “RESIST”.


Carbapenemase-Producing Enterobacteriaceae (CPE) represent a major health concern and any diagnostic tool allowing to help their laboratory detection can improve patient’s safety. Until today, non-molecular confirmatory testings of the presence of carbapenemases of Class A (KPC) and B (VIM, IMP, NDM) have been available.

Coris has launched the OXA-48 K-SeT, the first rapid test for the detection of the OXA-48 family carbapenemase.


RESIST Range will be progressively available.

Resist Range - Carbapenemase Producing Enterobacteriaceae


This first worldwide unique rapid test, named OXA-48 K-SeT, is aimed at the detection in 15 minutes of OXA-48-like-producing Enterobacteriacae from culture colonies.
Coris BioConcept also launched the KPC K-SeT kit whose aim is the identification of Carbapenemase KPC in bacteria culture.

Contact us for more information

Want to discover more about this new kit ? Clic on the video below to see how it works !


Interested in rapid Carbapenemase identification?



Launch of new respiratory products

Coris BioConcept is proud and pleased to announce the launch of three new respiratory products!

Streptococcus group A

Beta-hemolytic group A Streptococcus is one of the main bacteria responsible for upper respiratory tract infections, including sore throats, pharyngitis and scarlet fever.
Early diagnosis and antibiotic treatment of infections with group A Streptococcus help to drastically reduce the severity of symptoms and the incidence of serious complications including acute glomerulonephritis, rheumatic fever and peritonsillar abscess.

The Strep A-Strip test detects the specific antigen of group A streptococci directly from throat swab specimens.

Contact us for more scientific or technical information regarding this product.

Or visit the Streptococcus group A page.


Legionella pneumophila

Legionnaires’ disease is a serious pneumonia mostly (90%) caused by Legionella pneumophila which includes several serotypes with serogroup 1 accounting for over 80% of all infections.
The Legionella K-SeT is a direct antigen test to detect the Legionella pneumophila serogroup 1 antigen in urine samples.

The sensitivity and specificity are 97.6% and 100% which makes this test a prompt and suitable diagnostic tool in legionellosis diagnosis.

Contact us for more scientific or technical information regarding this product.

Or visit the Legionella pneumophila page.


Influenza A & B viruses

Rapid and reliable diagnosis of influenza is essential for identification of contagious patients and effective patient management.

The Coris “Influ A+B K-SeT” shows high sensitivity (90.9% type A and 91.8% type B) and specificity (100% type A et 98.1% type B).
The use of this test for diagnosis of influenza disease should enhance patient health care by enabling rapid and appropriate use of antiviral treatments and lowering inappropriate use of preventive antibiotic treatment still often prescribed by mistake.

Contact us for more scientific or technical information regarding this product.

Or visit the Influenza A & B viruses page.




Coris BioConcept

HAT Sero K-SeT (Human African Trypanosomiasis) : How to use the test !

HAT Sero K-SeT

Coris BioConcept launched last year the HAT Sero K-SeT. This kit is used for the detection of the Human African Trypanosomiasis (sleeping sickness), which is a life-threatening infection particularly virulent in sub-Saharan Africa.

Due to the hard working conditions scientists may face in Africa (extreme heat and humidity), this kit was specially developed to be easily used on the field. It doesn’t require power supply or any other equipment such as refrigerators which makes of HAT Sero K-Set a robust test that can stay at room temperature.


Here is below a new video showing how the HAT Sero K-SeT kit should be used.


©clair-obscur Productions


Don’t hesitate to go on the HAT product page to have more information.

Or simply contact us anytime to have answers to all the questions you might have regarding this video or the product in general.



HAT test to detect sleeping sickness – Market authorization in DRC !

Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study



Human African trypanosomiasis (HAT) is a life-threatening infection affecting rural populations in sub-Saharan Africa.

Large-scale population screening by antibody detection with the Card Agglutination Test for Trypanosomiasis (CATT)/Trypanosoma brucei (T b) gambiense helped reduce the number of reported cases of gambiense HAT to fewer than 10 000 in 2011.

Because low case numbers lead to decreased cost-effectiveness of such active screening, we aimed to assess diagnostic accuracy of a rapid serodiagnostic test (HAT Sero-K-SeT) applicable in primary health-care centres.


Dr Philippe Büscher PhD, Pascal Mertens PhD, Thierry Leclipteux PhD, Quentin Gilleman MSc, Diane Jacquet, Dieudonné Mumba-Ngoyi PhD, Patient Pati Pyana Vet Dr, Marleen Boelaert PhD, Veerle Lejon PhD



The whole paper is available on the following page: Human-African-Trypanosomiasis/Sciences



Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                 

Web traffic Optimisation

Design, Programming & hosting
Impact communication